Olymvax says its Staph vaccine works. The field has not seen that before.
On 11 July 2026, Chengdu Olymvax (688319.SH) disclosed that its Phase 3 trial of rFSAV, co-developed with Army Medical University, unblinded at 73.25% protective efficacy against a 60% pre-specified target in Chinese elective-surgery patients. It is a topline result that, if it holds up, would be the first pivotal-trial success anywhere in twenty years of Staphylococcus aureus vaccine development, and within a week an anonymous report challenging the numbers had wiped almost a third off the company's share price.
Sources: Chengdu Olymvax Biotech Co., Ltd., Voluntary Disclosure Announcement 2026-032, 11 July 2026 (translated by VacZine Analytics); Shanghai Stock Exchange STAR Market company filings, July-August 2026. Companion analysis to VacZine Analytics' Staphylococcus aureus (MRSA) BSI/SSI Vaccines Forecast, USA (VAMV002).
reported, vs. a 60% pre-specified target
reported through day 365 of follow-up
that have now failed in Phase 2b/3 since 2005
over the 5 trading days after the data was challenged
The 73.25% figure did not go unchallenged. Olymvax's 11 July filing was a voluntary disclosure, made ahead of its full clinical study report. Within two days, an anonymous report began circulating online questioning the case-count arithmetic behind the result. Olymvax's shares fell by approximately 31% over the following five trading days, including an 8% single-day drop on 17 July, the day the company issued a point-by-point rebuttal: it said the figures came from an independent third-party statistics team using standard Cox proportional-hazards methodology, filed a police report over the circulated document, and pledged to submit its complete analysis files to China's National Medical Products Administration (NMPA) for review. By late August, shares were still trading around CNY 30, roughly a third below their 52-week high of CNY 44.90, and little changed from where they closed the week the dispute broke.
Every major Staph vaccine has failed. This is the first that has not, yet.
Staphylococcus aureus has beaten every well-resourced vaccine programme that has reached a pivotal trial in the last two decades. Nabi's StaphVAX failed its confirmatory Phase III in 2005 in haemodialysis patients, showing no reduction in infections and taking two-thirds off Nabi's share price. Merck and Intercell's V710 was terminated in 2011 after an independent data monitoring committee found it unlikely to show a statistically significant benefit in cardiothoracic surgery patients, alongside a mortality and multi-organ-dysfunction imbalance that, while not itself statistically significant, was concerning enough to stop the trial outright. Pfizer's SA4Ag, tested in elective spinal-fusion patients, failed to demonstrate efficacy and was terminated in 2018. GSK's SA5Ag, published in March 2026, came in at minus 38.1% efficacy against recurrent skin infections, worse than placebo. Set against that run of results, a company-reported 73.25% efficacy against a pre-specified 60% target, in a genuinely comparable surgical population, would be the field's first pivotal-trial success if it survives scrutiny.
Same idea, different ingredients: the antigens both failures shared
Olymvax's own 11 July disclosure describes rFSAV only as covering "five antigen targets" via a "multi-dimensional target complex vaccine technology," without naming them. The published preclinical literature co-authored by the Olymvax and Army Medical University team (Zeng & Zou et al.) describes an earlier version of rFSAV built from four E. coli-expressed recombinant proteins presenting five targets: a modified staphylococcal protein A (SpA5, blocking an immune-evasion mechanism), a hemolysin/IsdB fusion protein (neutralising a pore-forming toxin while blocking iron acquisition), a detoxified enterotoxin B (mSEB), and the manganese transporter MntC, formulated with a simple aluminium phosphate adjuvant. VacZine Analytics has not confirmed this is identical to the exact Phase 3 formulation, but it is the best available public technical record. What stands out against the two Western failures: neither Pfizer's SA4Ag nor GSK's SA5Ag used this combination, and both leaned on capsular polysaccharides (CP5/CP8) as core antigens – a target class that has now failed in both of the field's most advanced Western candidates.
SA4Ag
- Antigens
- Capsular polysaccharides CP5/CP8, ClfA, MntC (4-antigen)
- Population
- Elective spinal-fusion surgery, USA
- Result
- Failed to demonstrate efficacy
SA5Ag (GSK3878858A)
- Antigens
- Protein A, alpha-haemolysin, CP5/CP8, ClfA (5-antigen)
- Adjuvant
- AS01E – a potent, proprietary system
- Result
- Minus 38.1% efficacy at 12 months
rFSAV
- Antigens (published record)
- SpA5, hemolysin/IsdB fusion, mSEB, MntC – no capsular polysaccharides
- Adjuvant
- Aluminium phosphate – a simple, established adjuvant
- Result
- 73.25% efficacy reported, disputed
The other divergence is patience, not chemistry. Olymvax's clinical trial approval for rFSAV was granted by China's then drug regulator in June 2015 – roughly eleven years before this Phase 3 readout. The trial itself ran across more than 60 centres nationally, led by Beijing Jishuitan Hospital, one of China's largest orthopaedic and trauma hospitals, in partnership with Army Medical University (formerly Third Military Medical University), an institution with a long research track record in wound and hospital-acquired infection. It is a methodical, decade-plus programme rather than a fast-follower leapfrog.
Five reasons to treat 73.25% as provisional, not proven
VacZine Analytics cannot independently verify either Olymvax's original figure or the anonymous report that disputed it – that adjudication sits with the trial's statisticians and, in time, with NMPA. What can be assessed is the structure of the disclosure itself, and on that basis there are several concrete reasons for caution that have nothing to do with which side of the dispute turns out to be right.
- It is a topline, pre-CSR disclosure. Olymvax's own announcement states the clinical trial summary report is still being written – this is a statistics team's headline output, not the completed record.
- No regulator has reviewed it. A registration filing requires clinical-data, manufacturing and R&D site inspections that have not yet taken place, by Olymvax's own account.
- It is under active, public challenge. An anonymous report disputing the case-count arithmetic remains unresolved; Olymvax has rebutted it and filed a police report, but the underlying data has not been independently adjudicated.
- The population and pathway are China-only. The trial's surgical population, standard of care and regulatory route do not automatically transfer to the US surgical and ESRD populations VacZine Analytics' own USA-focused model covers. Olymvax's risk disclosure commits only to "actively pursuing" overseas licensing – there is no confirmed FDA pathway.
- Olymvax's own filing flags substantial commercial uncertainty, even assuming approval: physician and patient acceptance of a first-in-class vaccine, potential future competition from better antibiotics, and what the company itself calls a "relatively long" market-adoption curve.
The full USA Staph vaccine forecast, tracking this development
This is one contested topline result inside a field with a twenty-year history of pivotal-trial failure. The live MarketVIEW model tracks the post-SA4Ag, post-SA5Ag competitor landscape – including Olymvax's rFSAV, Integrated Biotherapeutics' IBT-V02 and Eli Lilly/LimmaTech's LBT-SA7 – against scenario-based US revenue forecasts for surgical and ESRD populations.
View the Staph aureus report ← Back to homepage